Oncology in High-Risk Populations: Prevention, Screening and Early Detection in Hereditary and Sex-Specific Cancers

Abstract

Hereditary and sex-specific cancers represent a critical subset of oncology, demanding targeted prevention, screening, and early detection strategies in high-risk populations. Advances in genetic testing, molecular profiling, and risk stratification have enabled earlier identification and intervention, significantly impacting morbidity and mortality rates. This review synthesizes current epidemiological data, elucidates underlying mechanisms, and provides an up-to-date overview of clinical approaches, integrating recent advances, guideline recommendations, and practical implications for healthcare professionals managing high-risk individuals.

Introduction

Cancer risk is not uniformly distributed across populations; certain individuals possess a substantially elevated lifetime risk due to inherited mutations or sex-specific susceptibility. Hereditary syndromes, such as BRCA-associated breast and ovarian cancer, Lynch syndrome, familial adenomatous polyposis, and sex-specific malignancies such as prostate and cervical cancer, necessitate tailored clinical pathways. Recognizing and managing these high-risk groups is paramount for improving outcomes through prevention, vigilant screening, and timely intervention.

Epidemiology / Disease Burden

Hereditary cancers account for approximately 5-10% of all malignancies. BRCA1/2 mutations confer a 45-65% lifetime risk of breast cancer and up to 40% for ovarian cancer, while Lynch syndrome increases colorectal cancer risk up to 80%. Sex-specific cancers, such as prostate cancer—the second leading cause of cancer death in men—and cervical cancer, largely driven by persistent human papillomavirus (HPV) infection, underscore the importance of population-based and risk-adapted strategies. The disease burden is magnified by earlier onset and aggressive phenotypes in hereditary cases, often resulting in significant psychosocial and economic impacts.

Pathophysiology

Hereditary cancers arise from germline mutations in tumor suppressor genes (e.g., BRCA1/2, TP53, MLH1, MSH2) or oncogenes, leading to genomic instability and impaired DNA repair mechanisms. In Lynch syndrome, defective mismatch repair causes microsatellite instability, predisposing to colorectal and extracolonic malignancies. Sex-specific cancers often result from hormone-driven proliferation or chronic infection (e.g., HPV in cervical cancer). Understanding molecular pathways facilitates risk prediction, targeted surveillance, and precision therapies.

Risk Factors

Major risk factors include positive family history, identified pathogenic germline mutations, personal history of related cancers, and certain reproductive or hormonal factors. Environmental modifiers—such as tobacco use, obesity, and viral exposures—interact with genetic predisposition, modulating absolute risk. For prostate cancer, African ancestry and advancing age remain key risk determinants, while early menarche, late menopause, and nulliparity influence breast and ovarian cancer risks. Recognizing these factors is essential for individualized risk assessment and stratification.

Clinical Features

Hereditary and sex-specific cancers often present at a younger age and may exhibit bilateral, multifocal, or synchronous tumors. Red flag features include multiple primary malignancies, rare histologies (e.g., medullary breast cancer), and strong family clustering. For example, hereditary breast cancers may manifest as triple-negative phenotype, while Lynch syndrome-associated colon cancers typically occur in the proximal colon. Awareness of these clinical hallmarks is critical for prompt genetic evaluation and tailored management.

Diagnosis

Diagnosis begins with comprehensive personal and family history, followed by risk prediction models (e.g., BOADICEA, Manchester scoring). Genetic counseling and germline testing for high-penetrance genes are recommended for those meeting established criteria. Tumor testing (e.g., microsatellite instability, immunohistochemistry for mismatch repair proteins) can guide further germline evaluation. For sex-specific cancers, adjunctive diagnostic tools include PSA testing, HPV DNA assays, and liquid biopsy approaches, enhancing early detection in at-risk populations.

Treatment & Management

Management strategies encompass risk-reducing interventions (prophylactic surgery, chemoprevention), intensified surveillance, and personalized therapies. Bilateral mastectomy and salpingo-oophorectomy significantly lower cancer risk in BRCA mutation carriers. Colonoscopic surveillance and aspirin chemoprevention are standard in Lynch syndrome. Sex-specific cancers benefit from HPV vaccination, screening (e.g., Pap smear, HPV testing), and timely intervention. Multidisciplinary care, including psychosocial support and reproductive counseling, is vital for optimal outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of PARP inhibitors for BRCA-mutated breast and ovarian cancers, immune checkpoint inhibitors for mismatch repair-deficient tumors, and targeted hormonal therapies. Advances in next-generation sequencing enable broader panel testing, identifying moderate-penetrance genes and refining risk stratification. Circulating tumor DNA (ctDNA) and liquid biopsies show promise in early detection and monitoring. In sex-specific cancers, non-invasive HPV genotyping and risk-based screening algorithms are transforming early detection paradigms.

Guideline Recommendations

Professional societies (NCCN, ESMO, ASCO) advocate for universal genetic assessment in certain cancers (e.g., ovarian, pancreatic, high-grade prostate), cascade testing for relatives, and risk-adapted screening protocols. BRCA and Lynch syndrome carriers should initiate surveillance earlier and consider risk-reducing strategies. HPV vaccination is recommended for all eligible individuals, with tailored screening intervals for high-risk groups. Guidelines increasingly emphasize shared decision-making and integration of novel biomarkers in clinical algorithms.

Conclusion

Effective management of hereditary and sex-specific cancers in high-risk populations hinges on a multidisciplinary, evidence-based approach encompassing prevention, genetic risk assessment, personalized screening, and early intervention. Ongoing research and guideline evolution continue to refine strategies, aiming to reduce cancer burden and improve survival through precision oncology in those most vulnerable.